首页> 美国卫生研究院文献>Gut >Overexpression of nm23-H1 and nm23-H2 genes in colorectal carcinomas and loss of nm23-H1 expression in advanced tumour stages.
【2h】

Overexpression of nm23-H1 and nm23-H2 genes in colorectal carcinomas and loss of nm23-H1 expression in advanced tumour stages.

机译:在大肠癌中nm23-H1和nm23-H2基因的过表达和晚期肿瘤中nm23-H1表达的丧失。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Although a reduced expression of nm23 has been shown to correlate with a high metastatic potential in some human cancers, in colorectal cancers, conflicting data have been reported. As there are two homologous genes, nm23-H1 and nm23-H2, which encode the A and B subunits of nucleoside diphosphate kinase, efficient and simplified techniques were designed to selectively study nm23-H1 and -H2 expression in 35 colorectal cancers at both the protein and mRNA levels by immunoblotting, immunohistochemistry, and reverse transcription polymerase chain reaction (RT PCR) using specific antibodies and primers. Nm23-H1 and Nm23-H2 proteins were overexpressed in tumours compared with adjacent mucosa. This overexpression was lost, however, in some advanced cases: 89% and 81% of TNM (tumour, node, metastases) stages 0-II showed Nm23-H1 and -H2 overexpression, respectively, which significantly differed from 47% and 38% of stage III-IV tumours. Similar results were seen with nm23-H1 mRNA. Heterogenous labelling of tumoral cells was seen by immunohistological staining. This suggests a dichotomy: an overexpression of nm23-H1 and -H2 linked to early stages of cancer and a loss of nm23-H1 overexpression seen in more advanced stages. Therefore specific nm23-H1 determination should be evaluated as a prognostic factor in human colorectal carcinoma.
机译:尽管已表明nm23的表达降低与某些人类癌症中的高转移潜力相关,但在结直肠癌中,据报道存在相互矛盾的数据。由于存在两个同源基因nm23-H1和nm23-H2,它们编码核苷二磷酸激酶的A和B亚基,因此设计了有效而简化的技术来选择性地研究35种大肠癌中nm23-H1和-H2在两种情况下的表达。通过使用特异性抗体和引物进行的免疫印迹,免疫组织化学和逆转录聚合酶链反应(RT PCR)检测蛋白质和mRNA的水平。与邻近的粘膜相比,Nm23-H1和Nm23-H2蛋白在肿瘤中过表达。但是,在某些晚期病例中,这种过表达消失了:89%和81%的TNM(肿瘤,淋巴结,转移)阶段0-II分别显示Nm23-H1和-H2过表达,与47%和38%有显着差异III-IV期肿瘤。用nm23-H1 mRNA观察到相似的结果。通过免疫组织学染色观察到肿瘤细胞的异质标记。这表明了二分法:nm23-H1和-H2的过表达与癌症的早期阶段有关,而在更晚期阶段见到nm23-H1的过表达的丧失。因此,应将特定的nm23-H1测定作为人类大肠癌的预后因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号